Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events

Trial Profile

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone (Primary)
  • Indications Respiration disorders; Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms IMPROVE
  • Most Recent Events

    • 08 Mar 2019 Status changed from recruiting to completed.
    • 05 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Nov 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top